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The capacity of TNF to induce necrosis of solid 
tumours in vivo and its cytostatic and cytotoxic ac- 
tivities toward tumour cells in vitro promot.ed inten- 
sive research on this molecule and is very well 
established (Carswell et al., 1975; Haranaka et al., 
1984; Old, 1985 ; Palladino el al., 1987). Applica- 
tion of high-dose recombinant TNF in a combina- 
tion treatment protocol using isolation limp perfusion 
clearly demonstrates the antitumoral activity of TNF 
by selectively destroying the tumour vasculature 
(Lienard et a/., 1992). However, TNF, in addition 
to the antitumour effects, has a broad spectrum of 
biological effects that can complicate its use as an 
antitumor agent. The induction of IL1 (Dinarello ef 
al., 1986) and IFN-P (Kohase ef al., 1986) the en- 
hanced expression of HLA genes in tumour cells 
(Pfizenmaier et a/., 1987), or the supportive effect 
on NK (Mannel et a/., 1989) and LAK (McIntosh et 
al., 1989) activity might contribute to the beneficial 
antitumoral activity of TNF. 
The role of endogenous TNF in the pathophysiol- 
ogy of cancer and metastasis is controversially dis- 
cussed. Only limited information is available 
demonstrating enhanced levels in serum or tumour 
specimens of cancer patients (Naylor ef a/., 1990; 
Balkwill et al., 1987) and in tumour-bearing animals 
(Rakhmilevich and North, 1991; Mannel ef a/., 
1990). Such endogenous TNF might also contribute 
to tumour progression. TNF is able to activate en- 
zyme cascades that may enhance the tumour spread, 
e.g. proteases (Opdenakker and Van Damme, 1992; 
Dayer ef a/., 1985), to stimulate angiogenesis in vivo 
(Frater Schroder et al., 1987) and to increase the ad- 
herence of tumour cells to endothelium in virro (Rice 
et al., 1988; Dejana et al., 1988; Bereta et al., 1991). 
It has also been shown that TNF promotes the inva- 
sive growth of tumour cells in the peritoneum and 
their establishment as tumour nodules below the 
mesothelial surface (Malik et a/., 1989, 1990). 
TNF and endothelial adhesion 
Experiments concerning the influence of ex- 
ogenous TNF on metastasis had rather controversial 
results. In a murine fibrosarcoma model (Tomazic 
er a/., 1988), a lung cancer model (Schultz and Al- 
tom, 1990) and in melanoma models (Sylvester el al., 
1990; Lollini er al., 1990), inhibition of formation 
of metastases by rhTNF has been reported when 
rhTNF was given within 3 days of tumour cell inocu- 
lation. On the other hand, administration of rhTNF 
led to an increase in pulmonary metastasis when given 
1 h prior to i.v. inoculation of a human melanoma 
cell line into nude mice (Giavazzi et al., 1990) or 
promoted the implantation of human ovarian cancer 
xenografts in the peritoneal cavity of nude mice (Ma- 
lik et al., 1989). 
In an experimental metastasis model, mice 
received syngeneic fibrosarcoma cells (CFSl) i.v. The 
injection of either rmTNF or rhTNF 5 h prior to 
tumour cell inoculation led to a dose-dependent aug- 
mentation in the number of tumour colonies count- 
ed on the surface of the lungs after 12 days (fig. 1) 
(Orosz et al., 1993). The stronger metastasis- 
promoting activity of rmTNF compared to rhTNF 
demonstrated the described species preference of 
TNF (Kramer et al., 1988; Brouckaert et al., 1992) 
and might be explained by species-specific activities 
mediated via the mouse ~75 TNF receptor. Applica- 
tion of bacterial endotoxin (LPS) also augments 
metastasis, possibly by inducing endogenous TNF. 
Therefore, LPS contamination of the rmTNF and 
rhTNF preparation, respectively, was excluded by 
heating the TNF to 100°C for 15 min. This treatment 
destroyed the metastasis-enhancing capacity com- 
pletely. A significant increase in the colonies on the 
hrngs compared to control mice was observed only 
when rmTNF was given 5 h prior to or 1 h after 
turnour cells. Application of TNF 24 h before or 24 h 
and up to 4 days after tumour cell injection had no 
significant effect on pulmonary metastasis. Also, in 
vilro pretreatment of tumour cells with TNF had no 
influence on metastasis, in contrast to results 
described in a melanoma model (Lollini ef a/., 1990). 
These results suggest that the observed metastasis- 
promoting effect might reside in an influence of TNF 
on the interaction of circulating tumour cells with the 
endothelium supporting the arrest, diapedesis and ex- 
travasation of the tumour cells. 
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Fig. 1. Increase in experimental lung metastasis by cliffer- 
ent concentrations of rmTNF and rhTNF. 
Mice were given i.p. injections of different concentra- 
tions of rmTNF or rhTNF 5 h prior to i.v. CFSI tumor 
cell injection (3 x IO”). Control mice received the same 
volume of PBS. Results are expressed as mean+_SEM. 
n = I2 for control group; n = 6 for TNF treated groups. 
*** p < 0.001; ** p < 0.005; * p < 0.05. 
Since tumour-bearing mice showed an enhanced Preliminary evidence from our experiments using 
capacity for TNF production, the influence of en- thrombocytopenic mice also indicates an involvement 
dogenous TNF on the formation of lung metastases of platelets in the extravasation steps of metastasis. 
was investigated by injecting i.v. neutralizing anti- Ample data showing a correlation of metastasis with 
mouse TNF monoclonal antibodies (Vlq) (Echte- platelet aggregation can be found in the literature 
nacher el a/., 1990) 5 h before tumour cell inocula- (Mogi et al., 1991 ; Tzanakakis et al., 1991; Nierod- 
tion. The neutralization of endogenous TNF induced zik ef al., 1991 ; Sugimoto et al., 1991 ; Okoshi et al., 
a significant decrease in metastasis (table I), demon- 1991; Ordinas ef al., 1990). TNF leads to platelet ac- 
strating a supportive effect of endogenously tivation via stimulation of granulocytes (Renesto and 
produced TNF for metastasis. Whether this TNF ef- Chignard, 1991). The exact mechanisms, cells, and 
fect is due to enhanced expression of adhesion molecules involved in such a metastasis-provoking 
molecules on endothelial cells and/or tumour cells situation have yet to be analysed. 
by a direct action of TNF on these cells or whether 
it is mediated via additional cells, e.g. granulocytes 
or platelets, is currently being investigated. A recent 
report demonstrating abolishment of TNF-induced 
enhanced metastasis in a similar model by blocking 
adhesion strongly supports the hypothesis of adhe- 
sion promotion by TNF. It has been reported that 
synthetic peptides containing recognition sequences 
of cell adhesion molecules (i.e., Arg-Gly-Asp (RGD) 
in fibronectin and Tyr-Ile-Gly-Ser-Arg (YIGSR) in 
laminin) inhibit the development of tumour metasta- 
sis (Iwamoto et a/., 1987; Saiki er al., 1989). A modi- 
fied TNF molecule which carried the laminin-derived 
peptide YIGSR on the N-terminus did not enhance 
experimental metastasis, in contrast to unmodified 
TNF (Miyata et al., 1992). 
Tumour cell metastasis could be regulated in a 
similar way as lymphocyte migration from blood into 
tissue. Activation of integrins that mediate adhesion 
of T cells to the endothelium can be achieved by 
proteoglycan-immobilized cytokines, e.g. MIP-1P 
(Tanaka ef a/., 1993). A cellular proteoglycan that 
could serve the function of anchoring the activating 
cytokines is CD44, which has also been shown to be 
involved in regulation of metastasis (Arch et a/., 
1992). It could be speculated that enhancement of 
expression of such activating cytokines by TNF might 
be one possible mechanism by which TNF increases 
the adherence of tumour cells to the endothelium 
(Rice ef a/., 1988; Dejana et al., 1988; Bereta et al., 
1991). 
Table 1. Reduction of experimental metastasis by neutralization of endogenous TNF. 
Pretreatment n 
No. of lung metastases 
(mean f SEM) Range P 
PBS control 
Rat anti-mTNF (VIq) 
Rat IgG 
8 58.5 + 7.9 22-82 
6 9.6k5.6 l-31 < 0.005 
6 66.9+ 18.0 23-l 14 
Mice were treated i.p. with the indicated substances 5 h before i.v. CFSI tumour cell injection (3 x IO’). Animals were killed on day I I, 
lungs were removed and number of surface colonies was counted. 
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Table II. Enhancement of tumour cell proliferation rate in vivo by rmTNF. 
Pretreatment 
PBS control rmTNF 
AgNOR parameter (mean f SEM) (mean + SEM) P 
No. of AgNOR/cell 1.2f 1.2 8.4kO.7 < 0.001 
AgNOR area (ym*)/AgNOR 0.02 f 0.02 0.13+0.01 < 0.001 
AgNOR content/cell 9.4k9.4 65.8k5.6 < 0.001 
Mice received IO yg rmTNF or 100 yl PBS 5 h prior to i.v. turnour cell inoculation. Lungs were removed on day 5. fixed in formalin 
and AgNOR parameters were determined. n = 6 per group. 
TNF and cell activation 
Histological analysis of lung sections from 
rmTNF-pretreated mice 5 days after tumour cell 
inoculation showed more and larger pulmonary 
metastases in the septae of the lung parenchyma 
(fig. 2). Number and size of silver-stained proteins 
associated with nuclear organizer regions (AgNOR) 
per cell were determined on paraffin sections by dig- 
ital image analysis as a parameter for in vivo prolifer- 
ation (Ruschoff et al., 1990). Lung sections from 
rmTNF-pretreated mice showed a significantly en- 
hanced number of AgNOR dots, AgNOR area and 
AgNOR content per cell, indicating an augmented 
proliferation rate compared to the control group 
(fig. 2, table II). In vitro treatment with TNF, 
however, did not influence the proliferation rate of 
the fibrosarcoma cells, indicating that the augment- 
ed metabolic and proliferative activity in vivo might 
be host-dependent. Preliminary data with tumour 
cells growing as spheroids in three-dimensional cul- 
ture indicated opposing effects of TNF. At lower 
TNF concentrations, the size of the tumour spheroids 
was larger compared to TNF-free cultures, whereas 
at higher TNF concentrations, the tumour spheroids 
remained very small (unpublished results). Since TNF 
has been shown to exert growth stimulatory activa- 
ties on some cell types (Sugarman et al., 1985) 
growth-promoting and growth-inhibitory activities 
could be two overlapping functions of TNF. The 
mechanisms of the apparently opposing effects re- 
main to be analysed. 
A similar bimodal effect of TNF was also ob- 
served in angiogenesis. Whereas angiogenesis was in- 
hibited at high concentrations of TNF, low 
concentrations induced it (Fajardo et al., 1992). 
Thus, in a situation of low tissue concentration, TNF 
might support the growth of microvessels in neo- 
plasms and therefore eventually promote tumour 
growth. Recent data seem to support this hypothe- 
sis. Fibrosarcoma cells overexpressing tissue factor 
and growing as solid tumours showed better in vivo 
growth than those expressing low amounts (P. 
Nawroth, personal communication). Since TNF is an 
inducer of tissue factor expression on some cell types 
(Conway et al., 1989 ; Wiggins et al., 1990; Tanaka, 
1989) such indirect effector mechanisms might also 
be involved in the complex regulation of tumour 
growth. 
A positive correlation of stimulated immune sta- 
tus with poor prognosis and enhanced metastasis has 
been found (Reibnegger et al., 1987, 1991). The de- 
termination of enhanced levels of neopterin, a 
macrophage-derived product, and IL6 in tumour pa- 
tients served as parameters for the stimulated immune 
system. Increased neopterin and IL6 production are 
possible consequences of enhanced TNF production. 
In support of this observation is a recent study that 
directly documents increased blood TNF levels in 
metastatic cancer patients over those without 
me&stases (Ardizzoia et al., 1992). This correlation 
of exaggerated TNF secretion with neoplastic 
metastatic disease supports the pathological role of 
TNF in metastasis. 
Fig. 2. Histological sections of lung tissue from untreated mice (a,c) or TNF-treated mice (b,d) ex- 
hibiting small metastatic tumour nodules within alveolar septae (arrows). 
Haematoxylin/eosin stain; a) original x400, b) original x200. Nodule of metastatic tumour 
cells showing multiple silver stained NOR dots (AgNOR) within nuclei (arrows). c,d) AgNOR stain, 
original x 2,500. 
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